Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950142-23-002801
Filing Date
2023-11-17
Accepted
2023-11-17 08:00:38
Documents
2
Group Members
FORESITE CAPITAL FUND IV, L.P.FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT IV, LLCFORESITE CAPITAL MANAGEMENT V, LLCFORESITE CAPITAL OPPORTUNITY FUND V, L.P.FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLCJAMES B. TANANBAUM

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 eh230422217_13da4-knte.htm SC 13D/A 139785
2 EXHIBIT 1 eh230422217_ex01.htm EX-99.1 36278
  Complete submission text file 0000950142-23-002801.txt   177905
Mailing Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111 415-877-4887
Foresite Capital Fund V, L.P. (Filed by) CIK: 0001792204 (see all company filings)

EIN.: 843449937 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130
Business Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130 8582994699
Kinnate Biopharma Inc. (Subject) CIK: 0001797768 (see all company filings)

EIN.: 824566526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91893 | Film No.: 231416466
SIC: 2834 Pharmaceutical Preparations